Alnylam, Vir ally in deal worth potentially over $1bn; deal later expanded to include COVID-19
Executive Summary
In its second agreement announced on the same day Vir Biotechnology Inc. is partnering with Alnylam Pharmaceuticals Inc. in the development of up to five RNAi therapies for infectious diseases, including chronic hepatitis B virus.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice